Sharemaestro Newsreel

Perrigo (PRGO) Stock Trades At A Discount After A 62% Fall

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Perrigo stock has fallen sharply over the past few years, yet the current valuation checks suggest the market may now be pricing it …

Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of "Moderate Buy" from Brokerages

Liquidia Corporation (NASDAQ:LQDA) has received a "Moderate Buy" consensus rating from 11 brokerages, with an average 12-month price target of $86.18. The company recently surpassed quarterly earnings expectations, reporting $0.52 EPS against an anticipated $0.41, and revenue of $132.87 million, marking a significant year-over-year …

Elanco Animal Health (ELAN) Following FDA Emergency Use Authorization Has Valuation Back In Focus

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Elanco Animal Health (ELAN) is back in focus after receiving U.S. Food and Drug Administration Emergency Use Authorization for CLiK Extra wound spray, …

Is Elanco Animal Health (ELAN) Undervalued Following Its FDA Emergency Use Authorization?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Elanco Animal Health (ELAN) is back in focus after receiving U.S. Food and Drug Administration Emergency Use Authorization for CLiK Extra wound spray, …

ANI Pharmaceuticals (ANIP) Stock Slides As Cortrophin Concentration Clouds Profit Quality

SCYNEXIS (NASDAQ:SCYX) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded SCYNEXIS (NASDAQ:SCYX) from a "sell" to a "strong sell" rating. Despite this, the stock holds an overall "Hold" consensus rating with an average price target of $24.00. The biopharmaceutical company, which develops antifungal therapies, saw its shares rise by 0.8% …

Hims & Hers Health Earnings: What To Look For From HIMS

Hims & Hers Health Earnings: What To Look For From HIMS Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here's what to expect. Hims & Hers Health missed analysts' revenue expectations last quarter, reporting revenues …

Trulieve Cannabis (TRLV) Stock Hit By Harvest Accounting Distortion

Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze

Collegium Pharmaceutical (COLL) experienced a 1.2% stock increase after Q2 earnings, despite swinging from a profit to a net loss of US$15.1 million. While revenue grew to US$199.9 million, driven by its ADHD portfolio, the company faced a significant margin squeeze due to acquisition …

Aurora Cannabis Inc. 2027 Q1 - Results - Earnings Call Presentation (TSX:ACB:CA) 2026-08-08

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Executive Chairman and Chief Executive Officer - Miguel Martin Chief Financial Officer - Simona King Director of Strategic Finance and Investor Relations - Kevin Niland Full Conference Call …

Is Liquidia (LQDA) Overvalued After Its Third Straight Profitable Quarter?

Liquidia (LQDA) has achieved its third consecutive profitable quarter, driven by demand for its pulmonary hypertension therapy YUTREPIA and a significant financing agreement. Despite a recent surge in share price, leading to it trading above the average analyst price target, valuation models show conflicting …

Understanding Momentum Shifts in (ANIK)

This article analyzes Anika Therapeutics Inc. (ANIK) using AI models, highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for …

Earnings Preview: RMTI to Report Financial Results Pre-market on August 13

This article announces that RMTI is scheduled to report its financial results pre-market on August 13. The report will provide insight into the company's performance, which investors will be closely watching.

Zoetis (ZTS) Stock Sinks After Guidance Cut Deepens Profit Concerns

Zoetis (ZTS) stock fell almost 6% after the company cut its full-year guidance, now expecting adjusted diluted earnings per share between US$6.15 and US$6.25 and a mid to high single-digit decline in organic adjusted net income. This guidance cut was largely driven by a …

Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS

Half Year 2026 HUTCHMED (China) Ltd Earnings Call Transcript

This document contains the Half Year 2026 earnings call transcript for HUTCHMED (China) Ltd, held on July 30, 2026. Key points highlight strong China product sales and global growth for fruquintinib, alongside two new drug approvals. However, R&D expenses increased, other ventures revenue declined, …

SA Asks: What's the outlook for Big Pharma M&A?

[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a …

ANI Pharmaceuticals (ANIP) Could Be 31% Undervalued On Strong Q2 Results And Guidance Reset

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ANI Pharmaceuticals earnings beat and guidance reset ANI Pharmaceuticals (ANIP) reported better than expected Q2 2026 results and reaffirmed full year revenue guidance, while trimming its Cortrophin …

SIGA Technologies (SIGA) Stock Slips As Contract Uncertainty Trumps Profit

SIGA Technologies (SIGA) reported a profit in Q2 2026, but its stock still slipped due to contract uncertainty and declining revenue and EPS compared to the previous year. Despite a strong cash balance and no debt, the market is concerned about the volatility of …

Talphera (NASDAQ:TLPH) Upgraded at Wall Street Zen

Talphera (NASDAQ:TLPH) was upgraded to a "Hold" rating by Wall Street Zen, aligning with the overall "Hold" consensus among analysts, who have an average price target of $3.00. The company reported a narrower-than-expected quarterly loss of $0.04 per share, beating estimates. Institutional ownership is …

Zoetis Shares Approach 52-Week Low; Buybacks Support EPS Following Outlook Reduction

Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests – Quarterly Update Report

Download the Complete Report Here Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Key Takeaways: International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing …

Prestige Consumer Healthcare (PBH) Is Up 9.2% After Raising 2027 Outlook On Recent Acquisitions

In early August 2026, Prestige Consumer Healthcare reported fiscal 2027 first‑quarter revenue of US$265.71 million, up from US$249.53 million a year earlier, and raised its full‑year 2027 revenue outlook to US$1.29 billion–US$1.32 billion and projected GAAP diluted EPS of US$4.18–US$4.28, reflecting the addition of …

IM Cannabis closes $250,000 convertible note financing

IM Cannabis Corp. (NASDAQ:IMCC) has completed a $250,000 convertible note financing through a private placement with an institutional investor. The note carries an 8% annual interest rate, convertible into common shares at a specified price, and includes warrants to purchase additional common shares. The …

Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week

Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] …

Insider trades: Microsoft, Meta, Pfizer among notable names

[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small …

Takeda Pharmaceutical Co (TKPHF) Receives a Hold from Goldman Sachs

Goldman Sachs maintained a Hold rating on Takeda Pharmaceutical Co (TKPHF) based on a report released yesterday. Takeda Pharmaceutical Co currently holds a "Strong Buy" analyst consensus with a price target of $41.24, and its shares closed last Friday at Yen5,425.00. The company's market …

Organogenesis Holdings Inc (ORGO) Stock News Today

Canopy Growth reports fiscal first quarter revenue growth, improved margins

Canopy Growth Corporation reported a 13% year-over-year revenue increase to C$81.2 million in its fiscal first quarter of 2027, surpassing analyst estimates. The cannabis company also significantly narrowed its adjusted EBITDA loss by 59% to C$3.2 million, driven by revenue growth across all business …

Perrigo Company plc (PRGO) Stock Forecasts

This article provides an analyst report from Morningstar on Perrigo Company plc (PRGO), a consumer healthcare product manufacturer. The report highlights the company's recent infant formula recovery, which was met with excitement despite ongoing uncertainties. Perrigo specializes in private-label consumer health goods sold through …

Perrigo Company Plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Perrigo Company Plc recently exceeded its earnings expectations. This article will discuss what analysts anticipate for the company's future performance following this positive earnings report.

Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts

Argus has lowered its target price for Supernus Pharmaceuticals Inc. (SUPN) to $41.00, while the current stock price is $47.64. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system diseases. Investors can access the full report with a Yahoo Finance Silver …

Results: Perrigo Company plc Exceeded Expectations And The Consensus Has Updated Its Estimates

Perrigo Company plc (NYSE:PRGO) shareholders saw a 27% increase in their stake following better-than-expected quarterly profits, despite revenues meeting analyst forecasts. While analysts reconfirmed revenue estimates for 2026, they significantly increased per-share loss predictions, though the consensus price target remained unchanged at US$16.50. The …

Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler

Piper Sandler has reduced its price target for Amphastar Pharmaceuticals (AMPH) to $20.00 from $21.00, maintaining a "neutral" rating despite the company's recent earnings beat. While Amphastar exceeded analyst expectations with adjusted EPS of $0.91 and revenue of $183.9 million, overall analyst sentiment remains …

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research

Zacks Research has upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from a "hold" to a "strong-buy" rating. This upgrade comes despite a broader analyst consensus of "Moderate Buy" with a target price of $62.83. The company, which specializes in central nervous system therapies, also saw several institutional …

Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors?

The FDA recently approved Takeda Pharmaceutical's ORZEYFUL for narcolepsy type 1, providing a new entry into a rare disease market addressing orexin deficiency. While this approval strengthens Takeda's pipeline narrative, management has indicated it won't significantly alter this year's financial forecast. Investors should focus …